Zabopegdutide - D and D Pharmatech
Alternative Names: DD 01; DD-01 - D and D PharmatechLatest Information Update: 28 Apr 2026
At a glance
- Originator D and D Pharmatech
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in Puerto Rico (SC)
- 28 Apr 2026 No recent reports of development identified for phase-I development in Obesity in Puerto Rico (SC, Injection)
- 28 Apr 2026 No recent reports of development identified for phase-I development in Obesity in USA (SC, Injection)